MNPR - Monopar Therapeutics
57.61
1.810 3.142%
Share volume: 169,583
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$55.80
1.81
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-09-2024 | 08-09-2024 | 11-08-2024 | 05-13-2025 | 11-13-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | |||
| Operating expenses | 1.723 M | 1.789 M | 1.575 M | 3.222 M | 4.093 M | |
| Selling general and admin | 757.281 K | 657.806 K | 590.624 K | 1.578 M | 1.503 M | |
| Research and development | 966.110 K | 1.131 M | 984.278 K | 1.643 M | 2.590 M | |
| Total expenses | 1.723 M | 1.789 M | 1.575 M | 3.222 M | 4.093 M | |
| 3.79% | -11.96% | 104.57% | 27.04% | |||
| Operating income | -1.723 M | -1.789 M | -1.575 M | -3.222 M | -4.093 M | |
| Ebit | -1.723 M | -1.789 M | -1.404 M | -3.222 M | -4.093 M | |
| Pretax income | -1.641 M | -1.715 M | -1.304 M | -2.625 M | -3.438 M | |
| 4.51% | -23.96% | 101.26% | 30.96% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -1.641 M | -1.715 M | -1.304 M | -2.625 M | -3.438 M | |
| -4.51% | 23.96% | -101.26% | -30.96% |